Global /Brazil /Healthcare /Drug Manufacturers - General /HYPE3
chevron_leftBack
Hypera S.A. logo

Hypera S.A.

HYPE3
BVMF: HYPE3 Delayed
22.73BRL 3.3%
4.49 USD
As of 5 June 2026, Hypera S.A. has a market cap of $2.75B USD, ranking #5772 globally and #61 in Brazil. It ranks #453 in the Healthcare sector, and #178 in the Drug Manufacturers - General industry.
Global Rank
5772
Country Rank
61
Sector Rank
453
Industry Rank
178
Key Stats
Market Cap
$2.75BUSD
13.93B BRL
Enterprise Value
$4.31BUSD
21.8B BRL
Revenue (TTM)
$1.52BUSD
7.7B BRL
EBITDA (TTM)
$385.81MUSD
1.95B BRL
Net Income (TTM)
$236.03MUSD
1.2B BRL
EBITDA Margin
25%
Profit Margin
16%
PE Ratio
11.7
Forward PE
7.0
PS Ratio
1.8
PB Ratio
1.1
EV/EBITDA
10.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Breno Pires de Oliveira open_in_new
Employees
10,564
Founded
1999
Website
hypera.com.br open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
3.3% -2.7% 3.2% -13% -2% -1%

News

Loading...

Markets

Exchange Ticker Price
Brazil Stock Exchange (B3)
MIC: BVMF
PRIMARY
HYPE3
Hypera SA
ISIN: BRHYPEACNOR0
Shares Out.:
703.502M1 Shares Float: 433.343M2
TV:
SA:
YF:
GF:
BA:
MS:
22.73 BRL
Brazil Stock Exchange (B3)
MIC: BVMF
HYPE9
ISIN: BRHYPER01OR5
Shares Out.:
703.526M1 Shares Float: 406.307M2
TV:
SA:
YF:
GF:
BA:
MS:
24.19 BRL
OTC Markets
MIC: OTCM
HYPMY
Hypera SA ADR
ISIN: US44914U1060
TV:
SA:
YF:
GF:
BA:
MS:
4.60 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Hypera S.A.

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Similar Companies

Industry: Drug Manufacturers - General (Brazil)
Name
Market Cap diff.
PE
$458.83M
2.32B BRL
-83%
7.9
$341.97M
1.73B BRL
-88%
7.8
BIOM3
$203.73M
1.03B BRL
-93%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
28K%
38.1
JNJ
$547.28B
20K%
26.4
ABBV
$360.63B
13K%
97.4
$323.4B
256.25B CHF
12K%
19.9
AZN
$289.25B
215.59B GBP
10K%
27.6
NOVN
$276.26B
218.9B CHF
10K%
20.5
chevron_leftBack